Undecimal Bio launches with $18M to send RNA drugs beyond the liver
What's the deal? Undecimal BioDealroom has a profile for this one. Try Dealroom →, a Cambridge-based spin-out from Eleven Therapeutics, has raised $18 million in seed funding to develop siRNA therapeutics that reach tissues beyond the liver. The round was co-led by 4BIO CapitalDealroom has a profile for this one. Try Dealroom → and IQ CapitalDealroom has a profile for this one. Try Dealroom →, with participation from Verve VenturesDealroom has a profile for this one. Try Dealroom →, Harel TechDealroom has a profile for this one. Try Dealroom →, Entree Capital, Kerna VenturesDealroom has a profile for this one. Try Dealroom →, and Saras CapitalDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The company is building DELiveri, an AI-enabled platform that screens large combinatorial libraries of candidate ligands to find conjugates that carry RNA medicines into specific cell types. It turns cells into "molecular radars" that detect successful delivery at single-molecule resolution, then uses agentic AI to decode the structure-activity data and score the best candidates.
Why now? RNA interference has reshaped treatment of liver-expressed diseases, but reaching other tissues remains a key obstacle limiting the field. "The hard problem in RNAi was never the silencing, it was getting the molecule to the right cell," says chief executive officer and co-founder Yaniv Erlich.
What's the money for? The funding will advance Undecimal's renovascular programmes and expand the team at its laboratories in the Cancer Research UK Cambridge Institute. Existing treatments for these conditions mostly address symptoms rather than root causes.
The signal: The round lands amid a wave of European investment in RNA therapeutics and AI-driven biotech. Comparable 2026 deals include Dublin's Aerska (€32 million Series A), Paris-based WhiteLab Genomics (€23.2 million Series B), and Cambridge's STORM Therapeutics (€47.5 million Series C) — signalling growing investor appetite for next-generation genetic medicines.
Read more: EU-Startups, endpoints.news
Image credit: Generated with Gemini
